 The study examined the pharmacokinetic properties of tenephover disaproxil fumarate, TDF, and tenephover aliphenamide, TF, in South African adults living with HIV. It found that TAF led to lower tenephover plasma concentrations and lower toxicity than TDF, but there were limited data on its use in Africa. A joint model was developed to describe the population pharmacokinetics of tenephover given as TAF or TDF. The model showed that TAF quickly appeared as tenephover into the systemic circulation with first-order absorption while the remainder was sequestered intracellularly and released into the systemic circulation slowly. Once in plasma, tenephover followed two compartment kinetics and had a clearance of 44.7L-H, 40.2 to 49.5. This model can be used to predict exposure levels in patients and to simulate alternative regimens to inform future clinical trials. This article was authored by Ida N. Kawoma, Roland E. Wismann, Fumless Inc. Saadi, and others. We are article.tv. Links in the description below.